SIWA318H / SIWA Therap - LARVOL DELTA

Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer. (PubMed, Sci Rep) - "Immunohistochemical analyses of the tumor tissues showed a significant decrease in senescent cells in the tumor microenvironment of SIWA318H treated mice compared to that of control treated mice (p < 0.05). These results provide compelling evidence that SIWA318H is a promising novel therapeutic against pancreatic cancer."

Journal • Metastases • Preclinical • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CD34

SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study (PRNewswire) - "SIWA Therapeutics, Inc...announced...that SIWA's proprietary humanized monoclonal antibody, SIWA318H, is efficacious in an immune competent humanized mouse xenograft model for pancreatic cancer...Both the SIWA318H high dose and low dose treatment groups showed significant anti-tumor activity in a PSN1 human pancreatic cancer mouse xenograft tumor model by significantly reducing tumor growth (P-Value < 0.0001)....it expects to file its first IND with the FDA in 2023 for pancreatic cancer."

IND • Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor